Author: admin

  • Wimbledon 2025 results: Lucky loser Solana Sierra makes women’s history

    Wimbledon 2025 results: Lucky loser Solana Sierra makes women’s history

    A week ago, Solana Sierra was out of Wimbledon. Since then, she has picked up her fourth different room key as she keeps up her historic progress at the grass-court Grand Slam.

    The 21-year-old Argentine has become the first ‘lucky loser’ in the Open Era to reach the women’s singles fourth round at the All England Club.

    Lucky losers are players who lost in qualifying but end up in the main draw if others withdraw.

    Sierra only got 15 minutes’ notice before her first-round match that she would be playing, following an injury to Belgium’s Greet Minnen.

    And Sierra has grasped her opportunity with both hands, beating Cristina Bucsa 7-5 1-6 6-1 in the third round on Friday.

    “I remember I was really sad that day [I lost in qualifying], and today is like the best day of my life,” she told BBC Sport.

    “So it’s been really crazy. Seven days ago, I was out of the tournament, right now I’m into the second week. So it’s really crazy, and I’m just super happy.”

    She is the first Argentinian woman since Paola Suarez in 2004 to reach the last 16 at Wimbledon.

    By getting to that stage, Sierra will take home a minimum of £240,000 in prize money, adding considerably to her £330,000 career earnings until this point.

    “[I feel] super lucky,” said the world number 101, who beat Britain’s Katie Boulter in the second round. “But I think I also take the opportunity, and I really want to keep going and to keep dreaming in this tournament.”

    Sierra has extended her latest accommodation booking until Tuesday, which means if she beats Germany’s Laura Siegemund on Sunday, she will still have somewhere to stay until the quarter-finals.

    Continue Reading

  • 7 Rheumatology Updates to Know

    7 Rheumatology Updates to Know

    The second quarter of 2025 brought critical developments in rheumatology and autoimmune disease, as the FDA advanced several high-impact therapies and new data emerged to support innovative treatments. Regulatory milestones included the first-ever approval of inebilizumab for immunoglobulin G4-related disease, a landmark for this underserved patient population, and expanded indications for upadacitinib in giant cell arteritis, offering clinicians new tools for managing complex inflammatory conditions. Meanwhile, late-stage trial successes for TNX-102 SL in fibromyalgia and deucravacitinib in psoriatic arthritis hinted at promising future options for patients facing chronic pain and joint disease.

    Alongside these approvals and data readouts, advances in gout and lupus therapies underscored the ongoing evolution of targeted treatment strategies, with monthly pegloticase regimens showing feasibility for uncontrolled gout and belimumab reaffirming its role in systemic lupus erythematosus. However, an expansive analysis of rheumatoid arthritis trends painted a sobering picture of rising disease burden despite progress in treatment, highlighting the need for renewed global efforts in prevention and early intervention.

    Check out this Q2 2025 rheumatology month in review for a recap of HCPLive’s coverage of the top rheumatology news and research from the past few months:

    New Therapies Address Unmet Needs

    FDA Approves Inebilizumab (Uplizna) as First IgG4-RD Therapy for Adults
    The FDA has approved inebilizumab-cdon (Uplizna) as the first treatment for adults with immunoglobulin G4-related disease (IgG4-RD), addressing a significant unmet need in this rare autoimmune condition. This approval offers a new therapeutic option for patients previously reliant on less targeted treatments.​

    FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis
    Upadacitinib has received FDA approval for treating adults with giant cell arteritis, providing a new option for managing this inflammatory vascular disease. This expands the therapeutic arsenal for clinicians dealing with this challenging condition.​

    New Data Support TNX-102 SL Efficacy Ahead of PDUFA

    TNX-102 SL, a sublingual cyclobenzaprine formulation, showed significant efficacy in reducing pain and improving sleep disturbance in fibromyalgia patients in the phase 3 RESILIENT study, with benefits sustained over 14 weeks. The phase 1 PK study demonstrated that TNX-102 SL achieves higher dynamic peak cyclobenzaprine levels with reduced exposure to its active metabolite norcyclobenzaprine, which may contribute to more durable effects compared to oral formulations. If approved by its August 15, 2025 PDUFA date, TNX-102 SL could become the first new FDA-approved fibromyalgia therapy in over 15 years and a novel non-opioid analgesic option for this challenging chronic pain condition.

    EULAR Data Readouts

    Phase 3 Deucravacitinib Trial Meets ACR20 End Point in PsA

    The phase 3 POETYK PsA-1 trial demonstrated that deucravacitinib significantly improved joint and skin symptoms in adults with active psoriatic arthritis, meeting its primary endpoint with 54.2% of treated patients achieving ACR20 response at week 16 versus 34.1% on placebo. Key secondary endpoints were also met, including significant improvements in skin clearance, physical function, and quality of life measures, alongside evidence of inhibited radiographic progression. The safety profile of deucravacitinib was consistent with previous studies, with no new safety signals identified, supporting its potential as an oral, first-in-class TYK2 inhibitor for psoriatic arthritis management.

    Higher Dose Pegloticase Q4W Feasible for Uncontrolled Gout

    The phase 4 FORWARD trial suggests that once-monthly (Q4W) dosing of pegloticase at 16 mg or 30 mg, combined with methotrexate, can maintain serum urate control in most patients with uncontrolled gout, with 68-73% achieving sustained sUA responses through month 6. These findings indicate that less frequent pegloticase infusions could improve treatment logistics and adherence while maintaining comparable safety and efficacy to the established Q2W regimen. Importantly, infusion reaction rates were low and consistent with prior studies, supporting monthly pegloticase as a feasible alternative for patients struggling with the burden of biweekly therapy.

    Belimumab Superior to Placebo in Yielding Systemic Lupus Erythematosus Responses

    A meta-analysis of five Phase 3 trials has confirmed the efficacy of belimumab in systemic lupus erythematosus (SLE) using the BICLA responder index. The pooled analysis of over 3000 patients showed significantly higher BICLA response rates with belimumab versus placebo, particularly in those with high disease activity or serologic markers. The therapy was also more effective when combined with antimalarials, reinforcing its clinical utility in SLE management.

    Arthritis Burden Soars Globally

    Rheumatoid Arthritis Burden Has Surged Over Last 30 Years

    A large AI-driven analysis of rheumatoid arthritis (RA) trends across 953 global locations revealed a 13.2% rise in RA incidence since 1990, affecting 17.9 million people in 2021, with a shift toward younger populations. While age-standardized RA mortality dropped by 32.7% since 1980, global RA-related DALYs nearly doubled, highlighting an expanding burden despite medical advances. The study also pinpointed local hotspots—like West Berkshire, UK, with the highest incidence—and demonstrated that targeted interventions, such as smoking reduction, could substantially lower RA burden, emphasizing the importance of localized strategies beyond socioeconomic status alone.

    Continue Reading

  • Here’s When to Expect Apple’s Answer to Meta’s Ray-Ban Smart Glasses

    Here’s When to Expect Apple’s Answer to Meta’s Ray-Ban Smart Glasses

    Apple is reportedly developing smart glasses that could compete with the Meta Ray-Bans, but they are not expected to launch for a few more years.

    Earlier this week, Apple supply chain analyst Ming-Chi Kuo said that he expects Apple’s smart glasses to enter mass production in the second quarter of 2027. Similar to the Meta Ray-Bans, he said that Apple’s glasses will allow users to take photos, record videos, and listen to music, with both touch and hands-free voice control. These type of smart glasses are intended to let you capture a moment without needing to take your phone out of your pocket.

    Kuo said that Apple plans to offer multiple frame and material options for its smart glasses, but he did not indicate if it will partner with a major glasses brand, such as Ray-Ban or Oakley. Meta’s smart glasses are offered with three different Ray-Ban frames, including the iconic Wayfarer style that has been popular for decades.

    Like the Meta Ray-Bans, Kuo said Apple’s first glasses will not have built-in augmented reality displays. However, next-generation Meta Ray-Bans with such displays are expected to launch later this year, so Apple will remain well behind.

    Meta’s glasses are equipped with a 12-megapixel camera with 1080p video capture, dual speakers, five microphones, a touchpad on the right arm, and an LED that indicates when video recording is active. Meta says the glasses last up to four hours with a single charge, and up to 36 hours with a fully-charged carrying case.

    Meta Ray-Bans were released in September 2023, with U.S. pricing starting at $299. In February, Ray-Ban owner EssilorLuxottica announced that it had sold more than two million pairs of the glasses, making them a relative hit in a growing device category.

    For now, Apple’s only head-mounted device is the Vision Pro, which starts at a hefty $3,499. It is estimated that Apple has sold only 500,000 to 700,000 units of the Vision Pro, at best, since it launched in February 2024. Kuo believes that Apple’s smart glasses will be far more successful, with shipments reaching 3-5 million units or more in 2027.

    The unfortunate part is that 2027 remains quite a while away, with Apple’s competitors in this space innovating at a much faster pace.

    Continue Reading

  • Record growth of Chinese cars in UK

    Record growth of Chinese cars in UK

    One in 10 cars sold in the UK in June were made in China, according to the latest industry figures.

    New Chinese brands such as BYD, Jaecoo and Omoda are growing rapidly in the UK.

    There has been a particular surge over the past few months, at a time when most other G7 countries have levied significant extra tariffs against their imports.

    Around 18,944 cars made by Chinese-owned brands, including MG and Polestar, were sold in June, which is 10% of overall UK sales, according to the latest figures from the Society of Motor Manufacturers and Traders (SMMT). That is up from 6% in the same month a year ago.

    Across the first half of this year, more than 8% – or 1 in 12 – cars sold were Chinese, up from 5% in 2023 and 2024. This was mainly but not exclusively electric vehicles.

    By comparison a study by Jato Analytics for the first five months of the year put Chinese brands at 4.3% of the market across the EU, and just 1.6% in Germany and 2.7% in France. Spain was higher though at 9.2%.

    Its analyst Felipe Munoz said: “The fact that the UK has not imposed tariffs is a big opportunity for the Chinese, along with the popularity of electric cars.

    “MG is also playing like a local brand, and unlike France and Germany, the UK doesn’t have a big local industry to protect.”

    However, some industry grandees have warned that the UK industry will struggle to compete, and Britain might have to introduce quotas.

    Chinese firms and their franchises have been buying up car showrooms.

    “Chinese manufacturers are producing cars which are better, cheaper and more innovative in every sector of the market,” said John Neill, former SMMT President and ex-chief executive of Unipart.

    “If they are going to sell here we are going to have to get the Chinese to manufacture here.”

    The government has so far faced little pressure from existing suppliers on copying the tariffs imposed by the EU, US, and Canada on electric cars.

    The majority of EU member states backed big taxes being imposed on imports of EVs from China, which can be as high as around 45%, and Canada announced its imposition of a 100% tax on Chinese made EVs.

    The EU and China are in negotiations to replace the tariff with a minimum price system.

    Some Chinese manufacturers are also in the process of opening factories in the EU which could export across Europe including the UK tariff-free.

    The SMMT said that one in four buyers of new cars in the UK are now purchasing electric cars – although the transition to electric has been driven by “unsustainable” discounting by manufacturers, says Mike Hawes, the SMMT’s chief executive.

    “As we have seen in other countries, government incentives can supercharge the market transition,” he said.

    Continue Reading

  • Novel brain scan may predict age-related disease

    Novel brain scan may predict age-related disease

    Share on Pinterest
    An experimental brain scan may be able to accurately predict a person’s risk of age-related disorders. Image credit: Rafe Swan/Getty Images.
    • People age at different rates, partly due to genetics but largely because of lifestyle.
    • A person’s rate of aging can indicate how likely they are to develop age-related disorders, such as dementia.
    • Now, researchers have developed a method based on a single brain scan in middle age that could predict how fast a person is likely to age.
    • They suggest that their method, which can predict the aging rate of both brain and body, may detect who should implement lifestyle changes to reduce their risk of age-related illness.

    Some people appear to age more slowly than others. This is partly due to genetics, which studies suggest accounts for around 25% of the variation in longevity but is largely due to lifestyle and the environment.

    Modifications in lifestyle, such as following a healthy diet, exercising regularly, getting adequate sleep, not smoking, and not drinking alcohol to excess, can help slow a person’s rate of aging and delay or prevent age-related disorders.

    A person’s rate of aging is often referred to as their biological age — how old their cells are — which can vary greatly from their chronological age, or the number of years since their birth. Measuring this can be tricky.

    Now, a group of researchers from Duke, Harvard, and the University of Otago, New Zealand, have developed a method of predicting how fast a person will age, based on a single brain scan performed around the age of 45.

    In their study, which is published in Nature Aging, the researchers suggest that the Dunedin Pace of Aging Calculated from NeuroImaging (DunedinPACNI) could help researchers determine how aging affects health, and help them evaluate the effectiveness of anti-aging strategies.

    “The study developed and validated a new MRI-based biomarker called DunedinPACNI which shows not only a score for brain age, i.e. how old the brain looks, but also shows connections to cognitive decline and other health measures, allowing to perhaps predict how quickly a person ages and how their health will evolve later in life,” Madalina Tivarus, PhD, associate professor of Imaging Sciences and Neuroscience at the Del Monte Institute for Neuroscience at the University of Rochester, not involved in the study, told Medical News Today.

    “The idea of using a routine MRI brain scan to do a ‘aging check-up’ is very interesting and exciting,” Tivarus told us.

    This study builds on the Dunedin Study, previous research conducted in the same cohort of participants. This study, which followed a group of 1,037 people born in Dunedin, New Zealand in 1972–’73, looked at age-related changes in gene methylation to create an epigenetic clock.

    In the Dunedin Study, researchers regularly tested participants’ blood pressure, body mass index (BMI), glucose (blood sugar) and cholesterol levels, lung and kidney function, and even gum recession and tooth decay.

    Over almost 20 years, they used the overall pattern of change across these health markers to generate a score for how fast each person was aging.

    In the latest study, researchers used a single MRI scan of the brain performed when participants were aged 45, which they correlated with the Dunedin Study aging data. They then developed their DunedinPACNI to estimate rate of aging using only information from the MRI scan.

    They found that their prediction accuracy was in line with more established epigenetic methods.

    People with faster DunedinPACNI scores had several indicators of more rapid aging, including:

    • worse balance, slower gait, weaker lower and upper body strength, and poorer coordination
    • self-reported worse health and more physical limitations
    • poorer performance on cognitive function tests
    • greater childhood-to-adulthood cognitive decline
    • older physical appearance.

    Emer MacSweeney, MD, CEO and consultant Neuroradiologist at Re:Cognition Health, who was not involved in this research, highlighted how important brain imaging could be, telling MNT that:

    “The researchers observed that individuals with higher DunedinPACNI scores, indicating faster brain aging, were also more likely to experience health deterioration in other organ systems, such as cardiovascular and respiratory health. The fact that brain imaging can reflect systemic aging suggests the brain may serve as a biomarker for overall biological age, offering a non-invasive, accessible measure of aging processes throughout the body.”

    “This study is exciting because it shows that MRI scans might be used not just to detect disease, but also to track how the brain is aging long before problems begin. However, it’s still early days. While promising, DunedinPACNI still needs to be tested more widely in larger and more diverse populations across different ages, ethnicities, and health backgrounds. It did perform well across multiple large datasets, but more global validation is needed.”

    The researchers compared the DunedinPACNI with measures of hippocampal and ventricular volume, which are commonly used MRI-based measures of brain aging, using UK Biobank and ADNI participants.

    They found that faster DunedinPACNI was more consistently and strongly associated with poor cognition, poor health, frailty, and risk of dementia, disease and mortality than either of these measures.

    Tivarus was impressed by the study structure.

    “The study methodology has some important strengths such as it is using a robust, decades-long longitudinal dataset, uses sound statistical methods, and has been validated extensively using imaging data from other large studies,” she explained.

    However, she also pointed out that there were “some limitations, such as the specific population data used to train the model (mostly European ancestry, from a specific geographical location), its performance in younger or pediatric populations is untested, [and] it infers dynamic processes from one static image (one MRI snapshot).”

    “While I don’t think it is ready for clinical use, DunedinPACNI appears to be a promising imaging biomarker of biological aging,” Tivarus told us.

    Continue Reading

  • Corbyn’s new party – is it happening and could it damage Labour?

    Corbyn’s new party – is it happening and could it damage Labour?

    Sam Francis

    Political reporter

    Iain Watson

    Political correspondent

    Getty Images Zarah Sultana speaks with former Labour Party leader Jeremy Corbyn after addressing an audience at a fringe event for political festival The World Transformed.Getty Images

    Zarah Sultana and Jeremy Corbyn shared platforms when they were both Labour MPs

    High profile left winger Zarah Sultana has quit Labour and vowed to launch a new political party with Jeremy Corbyn.

    That, however, seems to have come as news to him.

    In a social media post, the former Labour leader congratulated Sultana on her “principled decision” to leave and said he was “delighted that she will help us build a real alternative”.

    But he said “the democratic foundations of a new kind of political party” were still taking shape and discussions were “ongoing”.

    Sultana appears to have jumped the gun, taking not just Corbyn but others involved in the project by surprise.

    But that does not mean it is not happening.

    There is no name yet – Arise and The Collective have been bandied about. Corbyn is thought to like the phrase “Real Change”, but not necessarily as a party name.

    No timetable for a launch has been agreed, although there has been talk of fielding candidates at next May’s local elections.

    But all of those involved in the project believe there is a huge gap in the market to the left of Sir Keir Starmer’s Labour Party, with millions of potential votes up for grabs.

    Are they right?

    And what would the arrival of a new socialist party mean for the Greens who have scooped up many left-wing voters in recent times – not to mention the Labour Party itself?

    It is very difficult to assess support for a party that does not yet exist, has no leader and no policies.

    Pollsters More In Common recently tested the sort of support a party to the left of Labour would have – specifically one led by Jeremy Corbyn.

    Their research suggested it could pick up 10% of the vote – reducing Labour’s standing by three points but far more dramatically eating in to support for the Greens, which would fall from 9% to 5% in the polls.

    Notably, a Corbyn-led party could become the country’s most popular party among 18- to 24-year-olds with 32% of the vote.

    Former Corbyn aide Andrew Murray said Sir Keir Starmer had “created the space” for a party to Labour’s left by ruthlessly expelling left wingers from the party and dropping his leadership campaign promises.

    Speaking to GB News’s Choppers Podcast, Murray said Labour’s 2017 vote – 3.2 million more than Sir Keir’s in 2024 – showed the scale of potential support for a new left-wing party.

    Thousands of votes had leaked away from the Tories to Reform UK at last year’s election, he added, and “there are similarly huge numbers of people who regard themselves as progressives and are looking for something different.”

    A veteran left-wing organiser, who did not wish to be named, told the BBC even with a double digit share of the national vote it is “quite hard for new parties to become positive forces in the UK”.

    “I think it could do quite a lot of damage to Labour and the Greens if it gets above a critical mass,” he said.

    Senior Greens have told the BBC they are not worried about a new insurgent party.

    Green leadership hopeful Zack Polanski said “anyone who wants to challenge Reform and this failing Labour government is a friend of mine”.

    But he added: “In the past there’s been lots of left-wing parties, but only the Green Party has endured and had sustained growth.”

    Polanski’s point was echoed by his leadership contest rival Adrian Ramsay, who currently co-leads the party, who said anyone looking for a “progressive alternative to Labour” should join the Greens.

    Any damage to the Greens could be limited by a “non-aggression” pact with the new party, running candidates on a joint ticket, for example, or agreeing to stand aside in certain circumstances.

    Jeremy Corbyn has been working for some time under the radar to turn the small group of independent MPs he co-ordinates into a full-blown political party which could stand candidates at the local elections next year.

    Last year, the Islington North MP united with Shockat Adam, Ayoub Khan, Adnan Hussain and Iqbal Mohamed – four independents that beat Labour candidates in the 2024 election with their pro-Palestinian stance in constituencies with large Muslim populations.

    On Wednesday he hinted that a new party could be on the way, telling ITV’s Peston he and his fellow pro-Gaza independents would “come together” and “there will be an alternative”.

    The MPs are united in their condemnation of Keir Starmer’s approach to the Gaza crisis, but we don’t know what their rest of their policy programme would be.

    We do not even know for certain that Jeremy Corbyn would be their leader. He is thought to favour a democratic convention to decide on leadership but others in the project are impatient to get on with it.

    Sultana is clearly keen to play a leading role, although her statement was carefully worded – she wants to co-lead the “founding” of a new party with Corbyn.

    One thing is clear – any new party will not be a reincarnation of the previous Corbyn project, as key figures on Labour’s left show no sign of leaving.

    Corbyn’s former shadow chancellor John McDonell said he was “dreadfully sorry to lose Zarah from the Labour Party” but is not expected to quit himself.

    The chair of the Labour party under Corbyn – Ian Lavery – told the BBC he planned to stay in the party until he retired.

    The Independent MPs were elected last year in areas where voters felt Labour wasn’t taking a strong enough line on Israel’s actions in Gaza.

    We don’t know how resonant the issue will be at the next election, four years away.

    But where Keir Starmer’s strategists might be concerned is that a new left-wing party might just reduce the Labour vote by enough in some seats to allow a second-placed Reform UK to sneak home.

    And Labour may have to be more mindful that it can lose votes on the left and not just the right.

    It was once seen as close to impossible to successfully launch a new political party in the UK, under Westminster’s first-past-the-post voting system.

    But Reform UK, which has five MPs and is currently ahead in the polls, has shown how volatile politics now is and the extent to which traditional party loyalties no longer matter.

    A well-known leader and some eye-catching policies could potentially redraw the map of mainstream politics.

    Thin, red banner promoting the Politics Essential newsletter with text saying, “Top political analysis in your inbox every day”. There is also an image of the Houses of Parliament.

    Continue Reading

  • Women's T20 Blast round-up: Kathryn Bryce leads Blaze charge – BBC

    Women's T20 Blast round-up: Kathryn Bryce leads Blaze charge – BBC

    1. Women’s T20 Blast round-up: Kathryn Bryce leads Blaze charge  BBC
    2. Recent Match Report – The Blaze Women vs Hampshire Women, Vitality Blast Women 2025, 34th Match | ESPN.com  ESPN
    3. NCCC News : BREAK BENEFICIAL BEFORE HAMPSHIRE CLASH, SAYS CUMMING  Trent Bridge
    4. Live Stream: The Blaze v Hampshire Hawks Women, Vitality Blast  Utilita Bowl

    Continue Reading

  • Lewis Hamilton ‘can dream of a strong’ British Grand Prix result after impressive Friday practice pace for Ferrari

    Lewis Hamilton ‘can dream of a strong’ British Grand Prix result after impressive Friday practice pace for Ferrari

    Ferrari’s Lewis Hamilton admits he “can dream of having a strong weekend” at the British Grand Prix after topping the first of Friday’s practice sessions.

    The seven-time World Champion enjoyed arguably his strongest Friday since joining the Scuderia at the start of 2025, having topped Free Practice 1 and finishing P3 in the afternoon session.

    Hamilton, a nine-time F1 winner at Silverstone, believes Ferrari’s pace was genuine and offers opportunities for Sunday’s race.

    “It was a really good day,” he said. “Great to see the crowd. Amazing to be out on track in a Ferrari here at Silverstone.

    “It’s pretty incredible and also with McLaren and Red Bull having upgrades, so for us to be in the mix still given they have had a step today, it’s really positive.

    “I definitely feel like we can dream of having a strong weekend for sure. Executing and putting it all together and extracting it is another thing but I’ll prepare myself the best I can to make sure we get the best result.”

    Hamilton secured his equal-best Grand Prix result for Ferrari last time out in Austria after finishing fourth and believes he is getting to grips with the SF-25 having been off the pace compared with team mate, Charles Leclerc.

    “I’m progressing a lot now with the car and much more comfortable knowing where it needs to be,” he added.

    “I think by FP2 we still weren’t where we needed to be, so definitely struggled a little bit more, but we know the changes that we need to make for the next session.”

    Leclerc also enjoyed a strong showing on Friday, finishing fourth in the first session and P2 during Free Practice 2.

    While missing some one-lap pace compared to pacesetter Lando Norris and McLaren, Leclerc believes Ferrari’s race pace will cause problems for the opposition on Sunday.

    “The day was good,” he said. We’ve been pretty strong so far so it’s positive. I think we still need to find some pace in Qualifying.

    “McLaren is once again probably the car to beat at the moment but in race pace I was happy. I’m finding my way, I’m changing quite a lot the car in weekends recently to try and find some pace in Qualifying.

    “For now, I don’t think I find a way for that, but in the race I’m really happy with where we are. I think we are very strong in the race but we’ve got to do a step forward in Qualifying.”

    Continue Reading

  • Arctic Ocean Stayed Open to Life During Ice Ages

    Arctic Ocean Stayed Open to Life During Ice Ages

    Led by the European Research Council Synergy Grant project Into the Blue – i2B, the research team studied sediment cores collected from the seafloor of the central Nordic Seas and Yermak Plateau, north of Svalbard. These cores hold tiny chemical fingerprints from algae that lived in the ocean long ago. Some of these algae only grow in open water, while others thrive under seasonal sea ice that forms and melts each year.

    “Our sediment cores show that marine life was active even during the coldest times,” said Jochen Knies , lead author of the study, based at UiT The Arctic University of Norway and co-lead of the Into The Blue – i2B project. “That tells us there must have been light and open water at the surface. You wouldn’t see that if the entire Arctic was locked under a kilometre-thick slab of ice.”

    One of the key indicators the team looked for was a molecule called IP25, which is produced by algae that live in seasonal sea ice. Its regular appearance in the sediments shows that sea ice came and went with the seasons, rather than staying frozen solid all year round.

    Simulating ancient Arctic climates

    To test the findings based on the geological records, the research team used the AWI Earth System Model – a high-resolution computer model – to simulate Arctic conditions during two especially cold periods: the Last Glacial Maximum around 21,000 years ago, and a deeper freeze about 140,000 years ago when large ice sheets covered a lot of the Arctic.

    “The models support what we found in the sediments,” said Knies. “Even during these extreme glaciations, warm Atlantic water still flowed into the Arctic gateway. This helped keep some parts of the ocean from freezing over completely.”

    The models also showed that the ice wasn’t static. Instead, it shifted with the seasons, creating openings in the ice where light could reach the water—and where life could continue to thrive. This research not only reshapes our view of past Arctic climates but also has implications for future climate predictions. Understanding how sea ice and ocean circulation responded to past climate extremes can improve models that project future changes in a warming world.

    “These reconstructions help us understand what’s possible—and what’s not—when it comes to ice cover and ocean dynamics,” said Gerrit Lohmann , co-author of this study, based at Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) and co-lead of Into The Blue – i2B. “That matters when trying to anticipate how ice sheets and sea ice might behave in the future.”

    Re-thinking the giant ice shelf theory

    Some scientists have argued that features on the Arctic seafloor suggest that a huge, grounded ice shelf once covered the entire ocean. But this new study offers another explanation.

    “There may have been short-lived ice shelves in some parts of the Arctic during especially severe cold phases,” said Knies. “But we don’t see any sign of a single, massive ice shelf that covered everything for thousands of years.”

    One possible exception could have occurred about 650,000 years ago, when biological activity in the sediment record dropped sharply. But even then, the evidence points to a temporary event, not a long-lasting frozen lid over the Arctic.

    Understanding the Arctic’s future

    The study sheds new light on how the Arctic has behaved under extreme conditions in the past. This matters because the Arctic is changing rapidly today. Knowing how sea ice and ocean circulation responded to past climate shifts helps scientists understand what might lie ahead.

    “These past patterns help us understand what’s possible in future scenarios,” said Knies. “We need to know how the Arctic behaves under stress—and what tipping points to watch for – as the Arctic responds to a warming world.”

    The full paper, “Seasonal sea ice characterized the glacial Arctic–Atlantic gateway over the past 750,000 years”, is available in Science Advances.

    This research is part of the European Research Council Synergy Grant project Into the Blue – i2B and the Research Council of Norway Centre of Excellence, iC3: Centre for ice, Cryosphere, Carbon, and Climate .

    /Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.

    Continue Reading

  • First large-scale stem cell bank created to investigate Alzheimer’s genetic risk factors

    First large-scale stem cell bank created to investigate Alzheimer’s genetic risk factors

    Alzheimer’s disease (AD) is a common, debilitating neurodegenerative disease affecting about 10 percent of people over the age of 65 and one third of people aged 85 and above. Besides environmental factors, the genes have a strong influence on whether or not a person develops AD during their lifetime. Through genome sequencing of DNA from large groups of healthy people and people with AD, some naturally occurring small changes in the DNA, known as genetic variants, were found to be more frequent in AD patients than in healthy people. As more and more of these AD-associated genetic “risk” variants are discovered, it is now possible to calculate a person’s individual polygenic risk score (PRS), meaning the likelihood of the person to develop AD, with high accuracy. Despite this progress, it is still largely unknown how genetic risk variants, or combinations thereof, cause AD in individual patients and more specifically, how risk variants impact the health and function of brain cells.

    To address this, researchers in the UK Dementia Research Institute at Cardiff University, UK, have now generated the first large-scale stem cell bank from over 100 individuals selected for extremes of AD PRS, which had previously been determined by genome sequencing. The results of the work are published today in Stem Cell Reports. About two thirds of the donors had been diagnosed with AD and had a relatively high PRS while one third were cognitively healthy, age-matched individuals with a low PRS. Blood cells from these individuals were genetically engineered to turn them into induced pluripotent stem cells (iPSCs), which are immature cells capable of generating all cell types of the body. The new “iPSC Platform to Model Alzheimer’s disease Risk” (IPMAR) resource will be made available to researchers worldwide to facilitate studies on the impact of risk variants in iPSC-based cellular models of AD in the lab. Ultimately, the resource can be used to increase our understanding of genetic risk factors linked to AD, and may inform the design of new, individualized treatments or prevention strategies.

    Source:

    International Society for Stem Cell Research

    Journal reference:

    Maguire, E., et al. (2025). Modeling common Alzheimer’s disease with high and low polygenic risk in human iPSC: A large-scale research resource. Stem Cell Reports. doi.org/10.1016/j.stemcr.2025.102570.

    Continue Reading